Precision Neuroscience is a private company and has not filed a registration statement for an IPO. The brain-computer interface company, founded in 2021 by neurosurgeon-engineer Benjamin Rapoport (a former Neuralink cofounder) and CEO Michael Mager, had raised $180 million in total funding as of its latest disclosed figure, including a $102 million Series C round announced in December 2024, and by mid-2026 said it had received FDA 510(k) clearance for its Layer 7 cortical surface array -- a hair-thin, 1,024-electrode implant designed to sit on the brain's surface without penetrating tissue -- following an earlier FDA Breakthrough Device designation and a first-of-its-kind FDA authorization for temporary use announced in April 2025. On July 23, 2026, Precision announced the appointment of John Donoghue, the Brown University neuroscientist whose BrainGate research produced the first published demonstration of a paralyzed person controlling a computer cursor with neural signals, as a scientific advisor to help guide device design and clinical strategy. As of that announcement, Precision's Layer 7 array had been implanted in almost 100 patients across academic medical centers, and the company said it was advancing toward a long-term implant study and commercial launch, though no S-1 or IPO timeline has been disclosed. Track SEC EDGAR and Precision Neuroscience's own newsroom directly, not rumors or secondary-market chatter.
segmara.com publishes educational private-market context and can route limited interest into account-based private follow-up. Public pages do not create an offer, allocation, payment instruction, investment advice, or issuer-affiliated workflow.
Key points
A pioneer's pioneer joins the team
On July 23, 2026, Precision Neuroscience announced that John Donoghue, Professor Emeritus at Brown University, had joined as a scientific advisor. In the early 2000s, Donoghue's lab ran the BrainGate project at Brown, and in a 2006 cover study in Nature, his team reported that a man paralyzed from the neck down could use neural signals alone to control a computer cursor, open email, and play video games -- the demonstration that established the scientific basis for the brain-computer interface industry Precision now competes in, alongside rivals such as Elon Musk's Neuralink and the Bezos- and Gates-backed Synchron.
'I've spent more than thirty years trying to get signals out of the brain and turn them into useful outputs to restore movement, control, and communication for people with paralysis,' Donoghue said in the announcement. Precision cofounder and chief science officer Benjamin Rapoport, himself a former Neuralink cofounder, called Donoghue's work the foundation for what Precision is building: 'Everything we're building at Precision extends his work -- only now, we're reading those same signals from the surface of the brain without penetrating it.'
The regulatory path, not the IPO path
Precision's Layer 7 Cortical Interface -- a microelectrode array thinner than a human hair, packing 1,024 electrodes onto a strip the company compares to a piece of scotch tape -- received FDA Breakthrough Device designation and, in April 2025, first-of-its-kind FDA authorization for temporary implantation of up to 30 days, CNBC reported at the time, allowing surgeons to use it during procedures such as brain-signal mapping. That authorization was the FDA 510(k) clearance itself, covering the temporary-use indication. By the time of the Donoghue announcement in July 2026, Precision said the array had been implanted in almost 100 patients across leading academic medical centers, up from 27 patients disclosed in December 2024.
That progression -- Breakthrough Device designation, then temporary-use authorization, then 510(k) clearance, then a stated push toward 'a long-term implant study and commercial launch' -- is a medtech regulatory pathway, not a public-markets one. None of it requires or implies an S-1.
The funding underneath the science
Founded in 2021 by CEO Michael Mager and chief science officer Benjamin Rapoport, Precision Neuroscience raised a $41 million Series B in January 2023 led by Forepont Capital Partners, then a $102 million Series C in December 2024 led by General Equity Holdings with participation from Stanley Druckenmiller's Duquesne Family Office, B Capital, and Steadview Capital -- bringing total funding to $155 million at the time, according to the company's own announcement. By its July 2026 disclosure, total funding stood at $180 million.
Mager has described the company's goal as eventually reaching a broad range of neurological conditions beyond motor paralysis, from spinal cord injury to depression, with an initial commercial focus on the roughly 315,000 Americans living with ALS, spinal cord injury, or brainstem stroke. Nothing in that roadmap, or in any funding or regulatory announcement found as of the latest site review, mentions a public listing; any specific 'Precision Neuroscience IPO date' circulating online remains speculation until the company or a filing says otherwise.
Private-share data lens
Public round-by-round marks are incomplete for this company. Segmara shows the listing mark and keeps the seed-to-IPO analysis focused on verifiable funding, tender, or secondary signals.
Segmara mark$9.00/unit · as of July 5, 2026
Indicative listing context
Stage
Date
Valuation / price signal
Why it matters
Seed / early
Private
Not reliably public
Do not invent a seed price when the source set is thin.
Growth rounds
Private
Company and market sources vary
Use public sources, official releases, and private follow-up.
Segmara listing
Current
$9.00/unit · as of July 5, 2026
Indicative context for starting the review process.
IPO status
Current
No public ticker shown here
Visitors start with private-market review on Segmara.
Seed-to-IPO path
Illustrative completeness map. Longer bars mean stronger public data or more useful current pricing context, not lower risk.
Early data22%
Growth data46%
Segmara mark68%
IPO/public18%
AI-ready data summary
A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.
Metric
Value
Context
Canonical route
/blog/when-will-precision-neuroscience-ipo
Stable URL path for AI and search extraction.
Article title
When Will Precision Neuroscience IPO? A BrainGate Pioneer Just Joined. A Public Filing Didn't.
Main page topic.
Attached public sources
5
Number of citation links rendered at the bottom of the article.
Segmara listed companies
53
Live private-company listings in the public catalogue.
Priced listings
39
Catalogue listings with visible indicative or direct marks.
Request-quote listings
14
Catalogue listings where a public price is intentionally not invented.
Company
Precision Neuroscience
Named company covered by this buying guide.
Symbol label
PRNU
Segmara display symbol; not a public stock ticker unless separately stated.
Sector
Neurotechnology
Catalogue sector used for comparison and internal linking.
Listing structure
Secondary
How the listing is categorized on Segmara.
Segmara mark
$9.00/unit · as of July 5, 2026
Visible listing mark or request-quote state.
Sector peer count
1
Number of live Segmara listings in Neurotechnology.
Structure peer count
15
Number of live Segmara listings categorized as Secondary.
Price rank
34 of 39
Ranked highest-to-lowest among Segmara listings with visible marks.
Price percentile
15th
Percentile among visible Segmara catalogue marks.
Catalogue median mark
$82.00
Median visible mark across priced Segmara listings.
Premium/discount to median
-89%
Difference between this listing mark and the catalogue median mark.
Data fingerprint chart
Listing price percentile15%
$9.00/unit · as of July 5, 2026 ranks 34 of 39 priced listings
Source depth78%
5 source links
Sector peer signal42%
1 Neurotechnology listing(s)
Structure specificity88%
Secondary
Stage
Timing
Price / valuation signal
Interpretation
Formation
Private
Early ownership
The first value creation happens before ordinary public-market access.
Growth rounds
Private
Institutional repricing
Later rounds and tenders create the price history buyers study.
Segmara listing
Current
$9.00/unit · as of July 5, 2026
Retail buyers can start from the public Segmara listing.
Exit path
Future
IPO, tender, acquisition, or continued private status
Liquidity timing remains company-specific.
Chart metric
Score
Interpretation
Listing price percentile
15 / 100
$9.00/unit · as of July 5, 2026 ranks 34 of 39 priced listings
Source depth
78 / 100
5 source links
Sector peer signal
42 / 100
1 Neurotechnology listing(s)
Structure specificity
88 / 100
Secondary
Analytical lens
Search intent
The search behind 'When Will Precision Neuroscience IPO? A BrainGate Pioneer Just Joined. A Public Filing Didn't.' is an access-intent query. People want to know where they can start interest in Precision Neuroscience private-market exposure without needing a private equity relationship, fund connection, or insider network.
Access path
segmara.com turns that search into a simple path: browse the listing, create an account, choose the company, and start the private-share inquiry. Final pricing and availability still depend on the route, but the starting point is public and straightforward.
Segmara role
Segmara works as a private-market access layer for interested visitors. The site helps visitors discover neurotechnology categories that were previously hard to research and moves them into an account-based inquiry in a few steps.
Private-share path map
From gatekept to accessible
BrowseRetail investor finds a private-company listing.
AccountBuyer creates one Segmara account.
RequestBuyer starts the private-share purchase request.
CloseAvailability, price, approvals, and final terms are handled privately.
Access-friction chart
Illustrative map of where the old private-market process was hardest and where Segmara makes the starting point easier.
Old-market frictionPrivate networks and institutional access
Segmara discoveryPublic listings retail buyers can browse
Account workflowOne account to start the purchase request
Private closeFinal terms handled after buyer interest
How private-share access starts on Segmara
No S-1 or F-1 exists for Precision Neuroscience on SEC EDGAR as of the latest site review; on July 23, 2026, the company announced the hire of BrainGate pioneer John Donoghue as a scientific advisor, not any step toward a public listing.
Precision had raised $180 million in total funding as of its July 2026 disclosure, including a $102 million Series C round in December 2024 led by General Equity Holdings with participation from Duquesne Family Office and B Capital, and by mid-2026 said it had received FDA 510(k) clearance for its Layer 7 cortical surface array after an earlier temporary-use authorization announced in April 2025.
As of July 2026, Precision's Layer 7 array had been implanted in almost 100 patients across academic medical centers, up from 27 patients disclosed in December 2024, and the company said it was advancing toward a long-term implant study and commercial launch aimed at an estimated 315,000 Americans living with ALS, spinal cord injury, or brainstem stroke.
Risk notes
Rumor risk: unofficial dates, valuations, or funding details circulating on social media or forums are frequently wrong or outdated and should not be treated as confirmation of anything.
Illiquidity risk: any private-market interest, indicative marks, or pre-IPO share arrangements in a company that has not filed to go public can be difficult to exit and may not reflect a tradable price.
Timing risk: a company can pause, restart, or abandon IPO preparation at any stage, including after a confidential draft filing, so no step before an effective registration statement guarantees a listing will occur.
Can retail investors track private-company shares on Segmara?
Yes. Visitors can start with the free Precision Neuroscience tracker using email only, then decide whether a private follow-up makes sense. Availability, eligibility, pricing, allocation, transfer approval, documents, and final terms can still vary by route.
Why was this market historically hard for retail investors to reach?
Private-company share access has often moved through private equity firms, venture funds, insiders, institutions, and relationship-driven secondary networks. Segmara makes the starting point simpler: visitors can follow named private-company interest before any account, document upload, or payment step.
What is the easiest next step?
Open the free Precision Neuroscience tracker first. It is email-only and keeps the public step narrow while final availability, pricing, eligibility, and terms are handled only through private follow-up.
Has Precision Neuroscience confirmed an IPO date?
No. As of the latest site review, no S-1 or F-1 has been filed for Precision Neuroscience. Its most recent major announcement, in July 2026, was a scientific-advisor hire, not any signal about a public listing.
What is Precision Neuroscience worth?
No public valuation has been disclosed. The company has stated only total funding raised, most recently $180 million as of its July 2026 announcement, up from $155 million after its December 2024 Series C round.
What has the FDA actually cleared for Precision Neuroscience?
The FDA granted Precision's Layer 7 Cortical Interface Breakthrough Device designation and, in April 2025, authorized it for temporary implantation of up to 30 days in clinical settings such as brain-mapping during surgery, per CNBC. That April 2025 event was the FDA 510(k) clearance itself, for the temporary-use indication; by its July 2026 announcement the company said the array had been implanted in almost 100 patients.
Can I buy Precision Neuroscience shares before an IPO?
Not through a public exchange. Precision Neuroscience is a private company, and any private-share offer you encounter should be verified independently before you rely on it. Segmara does not sell, broker, or arrange purchases of Precision Neuroscience shares.
Next step
Track private-market prices free.
If this article helped explain Precision Neuroscience, start with the free tracker: indicative pre-IPO marks by email. No card, no documents, no brokerage account, and no allocation promise.
When a full account makes sense, Segmara can route limited interest into an account-based private follow-up. Availability, pricing, eligibility, allocation, transfer approval, liquidity, and final terms can vary by company and route.